Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07285213 · ClinicalTrials.gov registry record · Phase 2

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

A Phase 2 study of Clostridioides Difficile Infection, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
230
Enrollment target
20
Study locations

NCT07285213 is a Phase 2 study of Clostridioides Difficile Infection that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 230 participants, below the 387-participant average among 6 other Clostridioides Difficile Infection trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07285213, a Phase 2 study of Clostridioides Difficile Infection, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
230 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.

Conditions Studied

Clostridioides Difficile Infection

Interventions

  • OTHER Placebo
  • DRUG AZD5148

Study Locations (20)

Florida

  • Research Site - Gainesville
  • Research Site - Homestead
  • Research Site - Jacksonville
  • Research Site - Miami Lakes
  • Research Site - Miramar
  • Research Site - Port Orange
  • Research Site - Tamarac
  • Research Site - Tampa

California

  • Research Site - Chula Vista
  • Research Site - Sacramento
  • Research Site - Torrance

Georgia

  • Research Site - Athens
  • Research Site - Atlanta

Kentucky

  • Research Site - Lexington
  • Research Site - Louisville

Arizona

  • Research Site - Phoenix

Connecticut

  • Research Site - Hamden

Idaho

  • Research Site - Idaho Falls

Illinois

  • Research Site - Burr Ridge

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2025-12-10
Est. Completion 2028-01-18
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07285213

The ClinicalTrials.gov registry entry for NCT07285213 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 387-participant average among 6 other Clostridioides Difficile Infection trials with a reported enrollment target (41% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Clostridioides Difficile Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07285213 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT07285213 about?

NCT07285213 is a clinical study titled "Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody". The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.

What is the current status of trial NCT07285213?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2025-12-10. Estimated completion is 2028-01-18.

What conditions does trial NCT07285213 study?

This clinical trial studies the following conditions: Clostridioides Difficile Infection.

What interventions are being tested in trial NCT07285213?

The interventions under investigation include: Placebo (OTHER), AZD5148 (DRUG).

Who is sponsoring clinical trial NCT07285213?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07285213 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clostridioides Difficile Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clostridioides Difficile Infection

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.